Effect of Transarterial Chemoembolization Plus Percutaneous Ethanol Injection or Radiofrequency Ablation for Liver Tumors

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   Web of Science ®Google Scholar
• EASL Clinical Practice. Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Gui CH, Baey S, D’Cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. Eur j Surgical Oncol. 2020;46(5):763–771. doi:10.1016/j.ejso.2020.01.004
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/s0140-6736(02)08649-x
   PubMed Web of Science ®Google Scholar
• Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. HPB Surgery. 2016;2016:6120143. doi:10.1155/2016/6120143
   PubMedGoogle Scholar
• Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002
   PubMed Web of Science ®Google Scholar
• Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010;51(4):1284–1290. doi:10.1002/hep.23466
   PubMed Web of Science ®Google Scholar
• Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology. 2013;57(4):1426–1435. doi:10.1002/hep.25832
   PubMed Web of Science ®Google Scholar
• Kim W, Cho SK, Shin SW, Hyun D, Lee MW, Rhim H. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdominal Radiology. 2019;44(6):2283–2292. doi:10.1007/s00261-019-01952-1
   PubMed Web of Science ®Google Scholar
• Cao S, Zou Y, Lyu T, et al. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression. Int j Hyperthermia. 2022;39(1):1–7. doi:10.1080/02656736.2021.1998660
   PubMed Web of Science ®Google Scholar
• Chen QW, Ying HF, Gao S, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2016;40(3):309–314. doi:10.1016/j.clinre.2015.07.008
   PubMed Web of Science ®Google Scholar
• Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a meta-analysis. Hepatology res. 2016;46(1):58–71. doi:10.1111/hepr.12568
   PubMed Web of Science ®Google Scholar
• Singh S, Melnik R. Thermal ablation of biological tissues in disease treatment: a review of computational models and future directions. Electromagn Biol Med. 2020;39(2):49–88. doi:10.1080/15368378.2020.1741383
   PubMed Web of Science ®Google Scholar
• Lencioni R, Cioni D, Della Pina C, Crocetti L. Hepatocellular carcinoma: new options for image-guided ablation. J Hepatobiliary Pancreat Sci. 2010;17(4):399–403. doi:10.1007/s00534-009-0233-0
   PubMed Web of Science ®Google Scholar
• Bartolozzi C, Lencioni R. Ethanol injection for the treatment of hepatic tumours. Eur Radiol. 1996;6(5):682–696. doi:10.1007/bf00187673
   PubMed Web of Science ®Google Scholar
• Lubienski A, Bitsch RG, Schemmer P, Grenacher L, Düx M, Kauffmann GW. Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy. RoFo. 2004;176(12):1794–1802. doi:10.1055/s-2004-813669
   PubMedGoogle Scholar
• Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol. 2010;52(3):380–388. doi:10.1016/j.jhep.2009.12.004
   PubMed Web of Science ®Google Scholar
• Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009;104(2):514–524. doi:10.1038/ajg.2008.80
   PubMed Web of Science ®Google Scholar
• Wang N, Guan Q, Wang K, et al. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol. 2011;28(4):1038–1043. doi:10.1007/s12032-010-9620-2
   PubMed Web of Science ®Google Scholar
• Ren Y, Cao Y, Ma H, et al. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study. BMC Cancer. 2019;19(1):983. doi:10.1186/s12885-019-6237-5
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez V, Brusadin R, López-Conesa A, et al. Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma. Langenbeck’s Arch Surgery. 2021;406(3):763–771. doi:10.1007/s00423-020-02056-x
   PubMed Web of Science ®Google Scholar
• Yun BY, Lee HW, Min IK, et al. Prognosis of Early-Stage Hepatocellular Carcinoma: comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers. 2020;12(9):8475. doi:10.3390/cancers12092527
   Web of Science ®Google Scholar
• Prince D, Liu K, Xu W, et al. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol. 2020;12:1758835920970840. doi:10.1177/1758835920970840
   Web of Science ®Google Scholar
• De Simone P, Vignali C, Petruccelli S, et al. Cost analysis of tumor downsizing for hepatocellular carcinoma liver transplant candidates. Transplant Proc. 2006;38(10):3561–3563. doi:10.1016/j.transproceed.2006.10.069
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. JAMA network open. 2021;4(9):e2126992. doi:10.1001/jamanetworkopen.2021.26992
   PubMed Web of Science ®Google Scholar
• Liu F, Chen M, Mei J, et al. Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. J Oncol. 2019;2019:6298502. doi:10.1155/2019/6298502
   PubMed Web of Science ®Google Scholar
• Kirikoshi H, Saito S, Yoneda M, et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatology res. 2009;39(6):553–562. doi:10.1111/j.1872-034X.2009.00490.x
   PubMed Web of Science ®Google Scholar
• Müller L, Hahn F, Auer TA, et al. Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: head-to-Head Comparison of Current Scoring Systems. Front Oncol. 2022;12:850454. doi:10.3389/fonc.2022.850454
   PubMed Web of Science ®Google Scholar
• Zhang D, Love T, Hao Y, et al. Tumor Size, Not Small Vessel Invasion, Predicts Survival in Patients With Hepatocellular Carcinoma. Am J Clin Pathol. 2022. doi:10.1093/ajcp/aqac001
   Web of Science ®Google Scholar